Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Noema Pharma AG
Modality
Small molecule
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05217628CT.gov An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia. | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Trigeminal Neuralgia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Basimglurant (this asset) | Noema Pharma AG | P2/3 | B · 57 |
| Neurotop | Beijing Tiantan Hospital | P4 | BB |
| Lidocaine | Beijing Tiantan Hospital | P4 | BB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Vanderbilt University Medical Center | P4 | BB |
| Galcanezumab | Duke University | P4 | BB |
| Sufentanyl | Xiangya Hospital of Central South University | P4 | BB |
| Ondansetron | Xiangya Hospital of Central South University | P4 | BB |
| Oxcarbazepine | Abbasi Shaheed Hospital | P4 | B |
| Vixotrigine | Biogen | P3 | B |
+24 more in the Trigeminal Neuralgia cohort
Other indications for Basimglurant
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Tuberous Sclerosis | — | P2 | B · 57 |
| Major Depressive Disorder | — | P2 | CCC · 55 |
| Depressive Disorder | — | P2 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Basimglurant in Trigeminal Neuralgia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/basimglurant-trigeminal-neuralgia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →